1-4-2024 31-3-2025 31-3-2025 No description of principal activity IRIS Elements Accounts Production 25.4 false 2 2 The company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies for the year ended 31 March 2025. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006. The director acknowledges their responsibilities to comply with the Companies Act 2006 in respect to accounting records and the preparation of financial statements. The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. In accordance with Section 444 of the Companies Act 2006, the Profit and loss account has not been delivered to the Registrar. These financial statements have been prepared in accordance with Financial Reporting Standard 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” including the provisions of Section 1A “Small Entities” and the Companies Act 2006. The financial statements have been prepared under the historic cost convention. Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, Value Added Tax and other sales taxes. Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life or, if held under a finance lease, over the lease term, whichever is the shorter. Investment property is shown at its most recent valuation. Any aggregate surplus or deficit arising from changes in fair value is recognised in profit or loss. Taxation for the year comprises current taxation. Tax is recognised in the Profit and loss account, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. As at 31 March 2025, the company owed Dr A O Elsheikh ( a director) amount totaling £405 (2024: £2,673). This loan is interest free and repayable on demand. iso4217:GBP iso4217:USD iso4217:EUR xbrli:shares xbrli:pure 12458958 2024-04-01 12458958 2025-03-31 12458958 2024-04-01 2025-03-31 12458958 2023-04-01 12458958 2023-04-01 2024-03-31 12458958 2024-03-31 12458958 ns14:PoundSterling 2024-04-01 2025-03-31 12458958 ns10:AuditExempt-NoAccountantsReport 2024-04-01 2025-03-31 12458958 ns10:FilletedAccounts 2024-04-01 2025-03-31 12458958 ns10:SmallEntities 2024-04-01 2025-03-31 12458958 ns10:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 12458958 ns5:CurrentFinancialInstruments 2025-03-31 12458958 ns5:CurrentFinancialInstruments 2024-03-31 12458958 ns5:ShareCapital 2025-03-31 12458958 ns5:ShareCapital 2024-03-31 12458958 ns5:RetainedEarningsAccumulatedLosses 2025-03-31 12458958 ns5:RetainedEarningsAccumulatedLosses 2024-03-31 12458958 ns10:Director1 2024-04-01 2025-03-31

| Company registration number: | 12458958
| Unaudited financial statements
| for the year ended 31 March 2025
| for
| MIDLAND MEDICAL SOLUTIONS LIMITED
| Pages for filing with the Registrar

| Company registration number: | 12458958
| MIDLAND MEDICAL SOLUTIONS LIMITED
| Balance sheet
| as at 31 March 2025
|  |  | 2025 |  | 2024
|  | Note |  | £ |  | £ |  | £ |  | £
| Fixed assets |  |  |  |  |  |  |  |  |
| Tangible assets | 4 |  | 42,674 |  |  |  | 49,181 |  |
| Investment property | 5 |  | 208,015 |  |  |  | 125,000 |  |
|  |  |  |  |  | 250,689 |  |  |  | 174,181
| Current assets |  |  |  |  |  |  |  |  |
| Cash at bank and in hand |  |  | 11,092 |  |  |  | 117,193 |  |
|  |  |  |  |  | 11,092 |  |  |  | 117,193
| Creditors: amounts falling due within one year |  |  |  |  | (805) |  |  |  | (10,969)
| Net current assets |  |  |  |  | 10,287 |  |  |  | 106,224
| Total assets less current liabilities |  |  |  |  | 260,976 |  |  |  | 280,405
| NET ASSETS |  |  |  |  | 260,976 |  |  |  | 280,405
| Capital and reserves |  |  |  |  |  |  |  |  |
| Called up share capital |  |  |  |  | 100 |  |  |  | 100
| Profit and loss account |  |  |  |  | 260,876 |  |  |  | 280,305
| TOTAL EQUITY |  |  |  |  | 260,976 |  |  |  | 280,405
| The company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies for the year ended 31 March 2025.
| The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
| The director acknowledges their responsibilities to comply with the Companies Act 2006 in respect to accounting records and the preparation of financial statements.
| 1

| Company registration number: | 12458958
| MIDLAND MEDICAL SOLUTIONS LIMITED
| Balance sheet - continued
| as at 31 March 2025
| The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
| In accordance with Section 444 of the Companies Act 2006, the Profit and loss account has not been delivered to the Registrar.
| Signed by:
| Dr A El Shiekh, Director |  |
| 23 December 2025 |  |
| 2

| MIDLAND MEDICAL SOLUTIONS LIMITED
| Notes to the financial statements
| for the year ended 31 March 2025
| 1 | Company information
|  | MIDLAND MEDICAL SOLUTIONS LIMITED is a private company registered in England and Wales. Its registered number is 12458958. The company is limited by shares. Its registered office is 4 Strensham Road, Balsall Heath, Birmingham, West Midlands, B12 9RR.
| 2 | Accounting policies
|  | Basis of preparing the financial statements
|  | These financial statements have been prepared in accordance with Financial Reporting Standard 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” including the provisions of Section 1A “Small Entities” and the Companies Act 2006. The financial statements have been prepared under the historic cost convention.
|  | Going concern
|  | In preparing these financial statements, the director has assessed whether there are any material uncertainties related to events or conditions that cast significant doubt upon the company's ability to continue as a going concern. In making this assessment, the director takes into account all available information about the future which is at least 12 months from the date that the financial statements are authorised for issue.
|  | The director considers that the company has adequate resources to continue in business for the foreseeable future and that it is appropriate to adopt the going concern basis in preparing the financial statements.
|  | Turnover
|  | Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, Value Added Tax and other sales taxes.
|  | Tangible fixed assets
|  | Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life or, if held under a finance lease, over the lease term, whichever is the shorter.
|  | Plant and machinery etc.:
|  | Motor vehicles | - | 10% straight line
|  | Computer equipment | - | 20% straight line
|  | Investment property
|  | Investment property is shown at its most recent valuation. Any aggregate surplus or deficit arising from changes in fair value is recognised in profit or loss.
| 3

| MIDLAND MEDICAL SOLUTIONS LIMITED
| Notes to the financial statements - continued
| for the year ended 31 March 2025
| 2 | Accounting policies - continued
|  | Taxation
|  | Taxation for the year comprises current taxation. Tax is recognised in the Profit and loss account, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.
|  | Current taxation assets and liabilities are not discounted.
|  | Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.
| 3 | Average number of employees
|  | During the year the average number of employees was 2 (2024 - 2).
| 4 | Tangible fixed assets
|  |  |  |  |  |  | Plant and machinery etc.
|  |  |  |  |  |  | £
|  | Cost |  |  |  |  |
|  | At 1 April 2024 |  |  |  |  | 65,677
|  | Additions |  |  |  |  | 1,300
|  | At 31 March 2025 |  |  |  |  | 66,977
|  | Depreciation
|  | At 1 April 2024 |  |  |  |  | 16,496
|  | Charge for year |  |  |  |  | 7,807
|  | At 31 March 2025 |  |  |  |  | 24,303
|  | Net book value
|  | At 31 March 2025 |  |  |  |  | 42,674
|  | At 31 March 2024 |  |  |  |  | 49,181
| 4

| MIDLAND MEDICAL SOLUTIONS LIMITED
| Notes to the financial statements - continued
| for the year ended 31 March 2025
| 5 | Investment property
|  |  |  | £
|  | Valuation |  |
|  | At 1 April 2024 |  | 125,000
|  | Additions |  | 83,015
|  | Disposals |  | -
|  | At 31 March 2025 |  | 208,015
| 6 | Related party transactions
|  | As at 31 March 2025, the company owed Dr A O Elsheikh ( a director) amount totaling £405 (2024: £2,673). This loan is interest free and repayable on demand.
| 5